Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IC 100 - InflamaCORE/ZyVersa Therapeutics

Drug Profile

IC 100 - InflamaCORE/ZyVersa Therapeutics

Alternative Names: IC 100-01; IC 100-02; IC 100-03; IC 100-04; IC 100-05; IC 100-06; IC100 - ZyVersa Therapeutics/InflamaCORE; ICCN-100; Inflammasome ASC Inhibitor IC-100

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InflamaCORE; University of Miami
  • Developer InflamaCORE; ZyVersa Therapeutics
  • Class Anti-inflammatories; Antidementias; Hepatoprotectants; Monoclonal antibodies; Urologics; Vascular disorder therapies
  • Mechanism of Action Inflammasome inhibitors; PYCARD protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Adult respiratory distress syndrome; Alzheimer's disease; Atherosclerosis; Metabolic disorders; Neurodegenerative disorders
  • Research Autoimmune disorders
  • No development reported Acute lung injury; Brain injuries; Diabetic nephropathies; Lupus nephritis; Multiple sclerosis; Non-alcoholic steatohepatitis; Spinal cord injuries; Stroke

Most Recent Events

  • 25 Mar 2024 ZyVersa Therapeutics plans preclinical studies for Metabolic disorders in Q2-2024
  • 28 Feb 2024 Preclinical trials in Metabolic disorders in USA (Parenteral) prior to February 2024
  • 28 Feb 2024 Pharmacodynamics data from preclinical trial in Metabolic disorders released by ZyVersa Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top